102 related articles for article (PubMed ID: 38754421)
1. ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity.
Maxwell MB; Hom-Tedla MS; Yi J; Li S; Rivera SA; Yu J; Burns MJ; McRae HM; Stevenson BT; Coakley KE; Ho J; Gastelum KB; Bell JC; Jones AC; Eskander RN; Dykhuizen EC; Shadel GS; Kaech SM; Hargreaves DC
Cell; 2024 May; ():. PubMed ID: 38754421
[TBL] [Abstract][Full Text] [Related]
2. ARID1A Deficiency Regulates Anti-Tumor Immune Response in Esophageal Adenocarcinoma.
Zhang L; Zheng Y; Chien W; Ziman B; Billet S; Koeffler HP; Lin DC; Bhowmick NA
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001638
[TBL] [Abstract][Full Text] [Related]
3. TREX1 Inactivation Unleashes Cancer Cell STING-Interferon Signaling and Promotes Antitumor Immunity.
Tani T; Mathsyaraja H; Campisi M; Li ZH; Haratani K; Fahey CG; Ota K; Mahadevan NR; Shi Y; Saito S; Mizuno K; Thai TC; Sasaki N; Homme M; Yusuf CFB; Kashishian A; Panchal J; Wang M; Wolf BJ; Barbie TU; Paweletz CP; Gokhale PC; Liu D; Uppaluri R; Kitajima S; Cain J; Barbie DA
Cancer Discov; 2024 May; 14(5):752-765. PubMed ID: 38227896
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors.
Wang L; Yang L; Wang C; Zhao W; Ju Z; Zhang W; Shen J; Peng Y; An C; Luu YT; Song S; Yap TA; Ajani JA; Mills GB; Shen X; Peng G
J Clin Invest; 2020 Nov; 130(11):5951-5966. PubMed ID: 33016929
[TBL] [Abstract][Full Text] [Related]
5. Cytosolic DNA accumulation promotes breast cancer immunogenicity via a STING-independent pathway.
Zhang J; Dai H; Huo L; Burks JK; McGrail DJ; Lin SY
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37907220
[TBL] [Abstract][Full Text] [Related]
6. Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis.
Zhou W; Liu H; Yuan Z; Zundell J; Towers M; Lin J; Lombardi S; Nie H; Murphy B; Yang T; Wang C; Liao L; Goldman AR; Kannan T; Kossenkov AV; Drapkin R; Montaner LJ; Claiborne DT; Zhang N; Wu S; Zhang R
Cancer Cell; 2023 Apr; 41(4):740-756.e10. PubMed ID: 36963401
[TBL] [Abstract][Full Text] [Related]
7. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S
PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682
[TBL] [Abstract][Full Text] [Related]
8. SAMHD1 silencing cooperates with radiotherapy to enhance anti-tumor immunity through IFI16-STING pathway in lung adenocarcinoma.
Li Y; Gao Y; Jiang X; Cheng Y; Zhang J; Xu L; Liu X; Huang Z; Xie C; Gong Y
J Transl Med; 2022 Dec; 20(1):628. PubMed ID: 36578072
[TBL] [Abstract][Full Text] [Related]
9. The exonuclease TREX1 constitutes an innate immune checkpoint limiting cGAS/STING-mediated antitumor immunity.
Lim J; Rodriguez R; Williams K; Silva J; Gutierrez AG; Tyler P; Baharom F; Sun T; Lin E; Martin S; Kayser BD; Johnston RJ; Mellman I; Delamarre L; West NR; Müller S; Qu Y; Heger K
Cancer Immunol Res; 2024 Mar; ():. PubMed ID: 38489753
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.
Li J; Wang W; Zhang Y; Cieślik M; Guo J; Tan M; Green MD; Wang W; Lin H; Li W; Wei S; Zhou J; Li G; Jing X; Vatan L; Zhao L; Bitler B; Zhang R; Cho KR; Dou Y; Kryczek I; Chan TA; Huntsman D; Chinnaiyan AM; Zou W
J Clin Invest; 2020 May; 130(5):2712-2726. PubMed ID: 32027624
[TBL] [Abstract][Full Text] [Related]
11. SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases.
Li Y; Yang X; Zhu W; Xu Y; Ma J; He C; Wang F
Cancer Cell Int; 2022 Nov; 22(1):347. PubMed ID: 36371186
[TBL] [Abstract][Full Text] [Related]
12. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.
Shen J; Ju Z; Zhao W; Wang L; Peng Y; Ge Z; Nagel ZD; Zou J; Wang C; Kapoor P; Ma X; Ma D; Liang J; Song S; Liu J; Samson LD; Ajani JA; Li GM; Liang H; Shen X; Mills GB; Peng G
Nat Med; 2018 May; 24(5):556-562. PubMed ID: 29736026
[TBL] [Abstract][Full Text] [Related]
13. ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response.
Bakr A; Corte GD; Veselinov O; Kelekçi S; Chen MM; Lin YY; Sigismondo G; Iacovone M; Cross A; Syed R; Jeong Y; Sollier E; Liu CS; Lutsik P; Krijgsveld J; Weichenhan D; Plass C; Popanda O; Schmezer P
Nucleic Acids Res; 2024 Apr; ():. PubMed ID: 38587186
[TBL] [Abstract][Full Text] [Related]
14.
Li L; Li M; Jiang Z; Wang X
Cells; 2019 Jul; 8(7):. PubMed ID: 31277418
[TBL] [Abstract][Full Text] [Related]
15. Targeting ARID1A mutations in cancer.
Mullen J; Kato S; Sicklick JK; Kurzrock R
Cancer Treat Rev; 2021 Nov; 100():102287. PubMed ID: 34619527
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome and molecular landscape of patients with ARID1A-loss gastric cancer.
Sun M; Gu Y; Fang H; Shao F; Lin C; Zhang H; Li H; He H; Li R; Wang J; Liu H; Xu J
Cancer Sci; 2024 Mar; 115(3):905-915. PubMed ID: 38148578
[TBL] [Abstract][Full Text] [Related]
17. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
18. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer.
Bosse T; ter Haar NT; Seeber LM; v Diest PJ; Hes FJ; Vasen HF; Nout RA; Creutzberg CL; Morreau H; Smit VT
Mod Pathol; 2013 Nov; 26(11):1525-35. PubMed ID: 23702729
[TBL] [Abstract][Full Text] [Related]
19. ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production.
Sun D; Qian H; Wang J; Xie T; Teng F; Li J; Xing P
Cell Commun Signal; 2022 Oct; 20(1):156. PubMed ID: 36229854
[TBL] [Abstract][Full Text] [Related]
20. Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs.
Diamond JM; Vanpouille-Box C; Spada S; Rudqvist NP; Chapman JR; Ueberheide BM; Pilones KA; Sarfraz Y; Formenti SC; Demaria S
Cancer Immunol Res; 2018 Aug; 6(8):910-920. PubMed ID: 29907693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
